Related Experiment Video
Updated: Dec 8, 2025
07:02
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
7.7K
Vitexin suppresses renal cell carcinoma by regulating mTOR pathways
Yuhong Li1, Qinghai Sun2, Hui Li3
1Department of Pharmacy, The First People's Hospital of Jingmen, Jingmen, China.
Translational Andrology and Urology
|September 18, 2020
Summary
Vitexin, a plant compound, inhibits renal cell carcinoma (RCC) growth and induces apoptosis by affecting key cellular pathways. This suggests vitexin holds promise as a potential therapeutic agent for RCC treatment.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Renal cell carcinoma (RCC) is a prevalent global malignancy.
- Vitexin, a natural bioactive compound, exhibits various health-protective properties.
- Understanding vitexin's role in RCC is crucial for developing new treatments.
Purpose of the Study:
- To investigate the anti-cancer effects of vitexin on renal cell carcinoma (RCC).
- To elucidate the molecular mechanisms underlying vitexin's action in RCC.
- To evaluate vitexin's therapeutic potential for RCC.
Main Methods:
- Cell proliferation assays (CCK-8, Edu staining) and apoptosis analysis (flow cytometry) were performed.
- Autophagy was assessed via immunofluorescence (LC3 spots) and western blotting.
- In vivo efficacy was studied in a mouse model (BALB/c nude mice), with molecular pathways analyzed by western blotting.
Main Results:
- Vitexin inhibited RCC cell growth and induced apoptosis in a dose-dependent manner.
- Vitexin promoted autophagy by modulating p62, Beclin1, and LC3II levels.
- Vitexin activated AMPK and JNK pathways while inhibiting the PI3K/AKT/mTOR pathway, and suppressed tumor growth in vivo.
Conclusions:
- Vitexin demonstrates tumor-suppressive effects in RCC cells through the AMPK/mTOR, PI3K/AKT/mTOR, and JNK signaling pathways.
- Vitexin exhibits significant anti-cancer activity in both in vitro and in vivo models of RCC.
- Vitexin represents a potential novel therapeutic candidate for the treatment of renal cell carcinoma.
Keywords:
AMPK/mTORRenal cell carcinoma (RCC)autophagyc-Jun N-terminal kinase (JNK)phosphatidylinositol 3-kinase/activates protein kinase/mammalian target of rapamycin (PI3K/AKT/mTOR)vitexinMore Related Videos
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
4.5K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.5K
02:34Inhibition of Cdk Activity
5.4K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
01:10Drugs that Destabilize Microtubules
3.2K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.2K
01:22PI3K/mTOR/AKT Signaling Pathway
5.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.0K
02:57Targeted Cancer Therapies
8.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.4K
01:15Drugs that Stabilize Microtubules
2.4K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.4K